Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2022, with a filing date of May 13, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| May 11, 2022 | Ordinary Shares (25p each) | £17.3438 | 14 Shares | London Stock Exchange (XLON) |
Note: Each transaction consisted of 7 partnership shares and 7 matching shares acquired at the same price.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is a regulatory disclosure of specific share purchases.
Investor Verification Checklist
- Executive Participation: Verify the list of executives participating in the Share Reward Plan, including CEO Emma Walmsley, President of Vaccines R. Connor, and CEO of ViiV Healthcare D. Waterhouse.
- Transaction Consistency: Confirm that all reported transactions occurred on May 11, 2022, at a uniform price of £17.3438 per share.
- Share Structure: Note that the volume for each individual was split equally between "partnership shares" and "matching shares."
- Regulatory Compliance: Ensure these notifications align with the company's broader insider trading policies and reporting requirements under UK and US regulations.